"After a median follow-up of 12.8 months, the estimated percentage of patients who were alive at 12 months was 89.9% in the pembrolizumab–axitinib group and 78.3% in the sunitinib group"approx. 432 patients in each arm
Another way to look at it is at 12 months approx. 43 death events occurred in pembro/Axi arm vs approx. 95 in Sunitinib arm.
The pfs hr was only .69. The only oddball statistic in this trial. Typically when tki is involved one would expect a better pfs hr vs OS hr. Atezo/bev acted more like I would expect in 1st line rcc trial combination Pfs hr much better than OS hr from what I recall.
I looked at all the sub group analysis on OS and every subgroup heavily favored pembro/axi and it wasnt even close. It is easy to pick out losers with conflicting subgroup analysis but one definitely doesnt exist here. Vegfr target is definitely doing something special and not many events to determine stat sig. Separation of km curve happens very early in this case for 1st line median OS is typically around 30 plus months. It might be interesting to see cross trial reference of percentage of patients alive in other 1st line rcc trials.